Mass Layoffs at the FDA Raise Concerns Over Neuralink's Future

The U.S. Food and Drug Administration has dismissed around 20 employees from its neurological and physical medicine devices office, including some responsible for reviewing Neuralink’s clinical trials. Experts warn that these layoffs could delay medical device approvals and impact the safety of Neuralink’s human trials.

Former FDA official Victor Krauthamer has expressed concerns about the potential intimidation of regulatory professionals overseeing the trials. Meanwhile, the Trump administration insists it will follow ethical guidelines, despite Elon Musk’s significant financial support for Trump’s re-election campaign.

With Neuralink currently testing brain implants that allow patients to control devices using only their thoughts, this sudden restructuring raises serious questions about regulatory oversight.

What do you think about these developments? Watch the full report and share your thoughts in the comments.